North American Contact Dermatitis Group Patch Test Results: 2021–2022
Dermatitis® · 01.09.2025 · 36 (5) · 464-476
DOI: 10.1089/derm.2024.0474 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Dermatitis®, online erschienen am 24.04.2025. Verfasst von Marie-Claude Houle und 13 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Dermatology, Centre Hospitalier Universitaire Québec, Laval University, Québec, Canada. Hauptthemen laut MEDLINE: Patch Tests, Dermatitis, Allergic Contact, Allergens. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Patch testing is an important diagnostic tool for the assessment of allergic contact dermatitis (ACD).
Objective
This study documents the North American Contact Dermatitis Group (NACDG) patch testing results from 2021 to 2022.
Methods
At 12 centers in North America, patients were tested in a standardized manner with a screening series of 80 allergens.
Results
Overall, 3056 patients were tested; 2200 (72.0%) had at least 1 positive/allergic patch test reaction and 1412 patients (46.6%) had a primary diagnosis of ACD. The most commonly positive allergens were nickel sulfate hexahydrate 5% and 2.5% petrolatum (24.9% and 22.1%, respectively), methylisothiazolinone (MI) (11.5%), hydroperoxides of linalool (10.1%), cobalt chloride hexahydrate (9.2%), and methylchloroisothiazolinone/methylisothiazolinone (9.0%). Compared with 2019–2020, prevalence of the top 20 allergens statistically increased for nickel ( P < 0.001), cobalt ( P < 0.01), gold ( P < 0.001), hydroperoxides of limonene ( P < 0.001), oleamidopropyl dimethylamine ( P < 0.01), dimethylaminopropylamine ( P < 0.01), and ammonium persulfate ( P < 0.001). MI positivity continued to decrease from its peak in 2017–2018. More than one-fifth of patients (n = 640, 21.1%) had at least one clinically relevant reaction to an allergen/substance not present in the NACDG screening series.
Conclusions
The epidemic of MI contact allergy in North America appears to continue its descent. Fragrance allergy is still very common, but the composition of fragrance allergy markers appears to be changing. Patch testing using a robust screening series, and supplemental allergens as indicated, is necessary for the comprehensive evaluation of ACD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Division of Dermatology, Centre Hospitalier Universitaire Québec, Laval University, Québec, Canada.
- Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
- Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.
- Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Marie-Claude Houle, Amber Reck Atwater, Erin M Warshaw, Brandon L Adler, Jonathan Silverberg
Zitieren
APA
Houle, M. C., DeKoven, J. G., Atwater, A. R., Reeder, M. J., Warshaw, E. M., Pratt, M. D., Belsito, D. V., Adler, B. L., Silverberg, J., Yu, J., Botto, N., Mowad, C. M., Dunnick, C. A., & Taylor, J. S. (2025). North American Contact Dermatitis Group Patch Test Results: 2021–2022. Dermatitis®, 36(5), 464-476. https://doi.org/10.1089/derm.2024.0474
Vancouver
Houle MC, DeKoven JG, Atwater AR, Reeder MJ, Warshaw EM, Pratt MD, et al. North American Contact Dermatitis Group Patch Test Results: 2021–2022. Dermatitis®. 2025;36(5):464-476. doi:10.1089/derm.2024.0474
BibTeX
@article{Houle2025,
author = {Houle, Marie-Claude and DeKoven, Joel G and Atwater, Amber Reck and Reeder, Margo J and Warshaw, Erin M and Pratt, Melanie D and Belsito, Donald V and Adler, Brandon L and Silverberg, Jonathan and Yu, JiaDe and Botto, Nina and Mowad, Christen M and Dunnick, Cory A and Taylor, James S},
title = {North American Contact Dermatitis Group Patch Test Results: 2021–2022},
journal = {Dermatitis®},
year = {2025},
volume = {36},
number = {5},
pages = {464--476},
doi = {10.1089/derm.2024.0474}
}
EUVIMED